Biotechnology companies often specialise in different phases of the drug-development cycle. They range from start-ups concentrating on early stage innovative technologies to large firms selling multibillion-dollar treatments. We believe the companies in the middle of this range show the most promise.
These firms have so-called “de-risked” drugs, which have just been approved by regulators and come through
